Ipca Laboratories Ltd.
IPCALAB · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,245.03.
Piotroski F-score 8/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%13.2%
- ✓Low debt (D/E < 0.5)0.08x
- ✓Positive free cash flow
- ✕Revenue growth > 10%6%
- ✓Earnings growing342%
- ✓Net margin ≥ 10%11.8%
- ✓Current ratio > 1.52.76
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 10.23
- ✓Piotroski ≥ 78/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 10.23.
- •High Piotroski quality score (8/9).
Opportunities
- •Earnings growing (342% YoY).
- •Trading in our value buy zone versus sector peers.
About Ipca Laboratories Ltd.
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various th
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.